Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma

Trial Profile

Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Acronyms ENDURANCE
  • Most Recent Events

    • 04 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top